Saturday, July 31, 2010

Nabi Biopharmaceuticals logs revenue from Glaxo sale

Nabi Biopharmaceuticals realized $10.5 million in revenue in its fiscal fourth quarter after collecting development payments from GlaxoSmithKline PLC for its PentaStaph drug. (NABI)

Post new comment

The content of this field is kept private and will not be shown publicly.